Appendix table 1: Estimated ratios of predicted geometric means of CD4 counts comparing year 3 post combination antiretroviral therapy (post-ART) with year 0, year 6 with year 3, and year 9 with year 6, according to baseline CD4 count. The same comparisons for estimated ratios of predicted geometric means of CD8 counts and the geometric CD4:CD8 ratio. 95% confidence intervals displayed within brackets.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| BaselineCD4 countcells/mm3 | 0 to 3 years post-ART |  | 3 to 6 years post-ART |  | 6 to 9 years post-ART |
| CD4 count | CD8 count | Ratio CD4:CD8 |  | CD4 count | CD8 count | Ratio CD4:CD8 |  | CD4 count | CD8 count | Ratio CD4:CD8 |
| 0 to 24 | 18.1\*[17.6, 18.5] | 2.39[2.33, 2.44] | 7.57[7.37, 7.78] |  | 1.26[1.23, 1.29] | 0.91[0.90, 0.93] | 1.38[1.35, 1.41] |  | 1.20[1.17, 1.23] | 1.00[0.98, 1.02] |  1.20[1.17, 1.22] |
| 25 to 49 | 6.55[6.36, 6.74] | 1.69[1.64, 1.73] | 3.88[3.76, 4.01] |  | 1.24[1.21, 1.28] | 0.94$[0.92, 0.96] | 1.32[1.28, 1.36] |  | 1.16[1.13, 1.19] | 0.98[0.96, 1.00] |  1.18[1.15, 1.21] |
| 50 to 99 | 3.79[3.70, 3.87] | 1.32[1.30, 1.35] | 2.86[2.79, 2.93] |  | 1.23[1.20, 1.26] | 0.95[0.94, 0.97] | 1.29[1.26, 1.32] |  | 1.13[1.10, 1.15] | 0.95[0.94, 0.97] |  1.18#[1.16, 1.21] |
| 100 to 199 | 2.29[2.26, 2.33] | 1.00[0.99, 1.01] | 2.29[2.26, 2.33] |  | 1.15[1.13, 1.17] | 0.98[0.97, 0.99] | 1.18[1.16, 1.19] |  | 1.09[1.08, 1.11] | 0.97[0.96, 0.98] |  1.13[1.12, 1.15] |
| 200 to 349 | 1.78[1.76, 1.80] | 0.84[0.84, 0.85] | 2.11[2.09, 2.13] |  | 1.07[1.06, 1.08] | 0.97[0.97, 0.98] | 1.10[1.09, 1.11] |  | 1.06[1.05, 1.08] | 0.96[0.95, 0.97] |  1.11[1.10, 1.12] |
| 350 to 499 | 1.44[1.41, 1.46] | 0.82[0.81, 0.84] | 1.74[1.71, 1.77] |  | 0.99[0.97, 1.01] | 0.97[0.95, 0.98] | 1.02[1.00, 1.04] |  | 1.06[1.05, 1.08] | 0.95[0.94, 0.96] |  1.12[1.10, 1.13] |
|  500 | 1.11[1.08, 1.13] | 0.84[0.83, 0.86] | 1.31[1.28, 1.34] |  | 0.90[0.88, 0.92] | 0.96[0.95, 0.98] | 0.93[0.91, 0.95] |  | 1.05[1.03, 1.07] | 0.95[0.94, 0.96] |  1.11[1.09, 1.13] |

\* Interpretation of geometric ratio: Among patients with baseline CD4 count 0 to 24 cells/mm3, geometric mean CD4 count at 3 years was just over 18 times higher than the geometric mean CD4 count at start of ART.

$ Interpretation of geometric ratio: Among patients with baseline CD4 count 25 to 49 cells/mm3, geometric mean CD8 count at 6 years post-ART was 6% lower compared to the geometric mean CD8 count at 3 years post-ART.

# Interpretation of geometric ratio: Among patients with baseline CD4 count 50 to 99 cells/mm3, geometric CD4:CD8 ratio at 9 years post-ART was 18% higher than the geometric CD4:CD8 ratio at 6 years post-ART.

Appendix table 2: Among patients virologically suppressed (≤1000 copies/mL) from 6 months after starting combination antiretroviral therapy, estimated ratios of predicted geometric means of CD4 counts comparing year 3 post-ART with year 0, year 6 with year 3, and year 9 with year 6, according to baseline CD4 count. The same comparisons for estimated ratios of predicted geometric means of CD8 counts and the geometric CD4:CD8 ratio. 95% confidence intervals displayed within brackets.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| BaselineCD4 countcells/mm3 | 0 to 3 years post-ART |  | 3 to 6 years post-ART |  | 6 to 9 years post-ART |
| CD4 count | CD8 count | Ratio CD4:CD8 |  | CD4 count | CD8 count | Ratio CD4:CD8 |  | CD4 count | CD8 count | Ratio CD4:CD8 |
| 0 to 24 | 25.7\*[24.9, 26.5] | 2.47[2.40, 2.55] | 10.4[10.1, 10.7] |  | 1.30[1.26, 1.35] | 0.87[0.85, 0.90] | 1.49[1.44, 1.54] |  | 1.15[1.12, 1.19] | 0.99[0.96, 1.01] |  1.17[1.13, 1.21] |
| 25 to 49 | 8.49[8.18, 8.79] | 1.71[1.65, 1.77] | 4.96[4.76, 5.15] |  | 1.27[1.22, 1.32] | 0.91$[0.88, 0.94] | 1.39[1.34, 1.45] |  | 1.15[1.11, 1.19] | 0.98[0.95, 1.00] |  1.18[1.14, 1.22] |
| 50 to 99 | 4.64[4.52, 4.77] | 1.33[1.29, 1.36] | 3.49[3.39, 3.59] |  | 1.26[1.22, 1.29] | 0.93[0.91, 0.95] | 1.35[1.31, 1.39] |  | 1.10[1.07, 1.13] | 0.94[0.92, 0.96] |  1.17#[1.13, 1.20] |
| 100 to 199 | 2.64[2.59, 2.68] | 0.97[0.95, 0.98] | 2.72[2.68, 2.77] |  | 1.20[1.18, 1.23] | 0.97[0.95, 0.98] | 1.24[1.22, 1.27] |  | 1.08[1.06, 1.10] | 0.96[0.95, 0.98] |  1.12[1.10, 1.15] |
| 200 to 349 | 1.98[1.96, 2.00] | 0.80[0.79, 0.81] | 2.48[2.45, 2.52] |  | 1.13[1.11, 1.14] | 0.96[0.95, 0.97] | 1.17[1.15, 1.19] |  | 1.05[1.04, 1.07] | 0.96[0.95, 0.97] |  1.10[1.08, 1.12] |
| 350 to 499 | 1.63[1.59, 1.66] | 0.76[0.74, 0.77] | 2.14[2.10, 2.19] |  | 1.08[1.05, 1.11] | 0.95[0.93, 0.97] | 1.14[1.11, 1.17] |  | 1.03[1.00, 1.05] | 0.94[0.92, 0.96] |  1.09[1.06, 1.12] |
|  500 | 1.27[1.23, 1.30] | 0.77[0.75, 0.79] | 1.65[1.60, 1.69] |  | 1.04[1.00, 1.07] | 0.95[0.93, 0.98] | 1.09[1.05, 1.13] |  | 1.02[0.99, 1.06] | 0.95[0.93, 0.97] |  1.08[1.04, 1.11] |

\* Interpretation of geometric ratio: Among virologically suppressed patients with baseline CD4 count 0 to 24 cells/mm3, geometric mean CD4 count at 3 years was close to 26 times higher than the geometric mean CD4 count at start of ART.

$ Interpretation of geometric ratio: Among virologically suppressed patients with baseline CD4 count 25 to 49 cells/mm3, geometric mean CD8 count at 6 years post-ART was 9% lower compared to the geometric mean CD8 count at 3 years post-ART.

# Interpretation of geometric ratio: Among virologically suppressed patients with baseline CD4 count 50 to 99 cells/mm3, geometric CD4:CD8 ratio at 9 years post-ART was 17% higher than the geometric CD4:CD8 ratio at 6 years post-ART.

Appendix table 3: Among patients who experienced a virological failure (>1000 copies/mL) from 6 months after starting combination antiretroviral therapy (ART), estimated ratios of predicted geometric means of CD4 counts comparing year 3 post-ART with year 0, year 6 with year 3, and year 9 with year 6, according to baseline CD4 count. The same comparisons for estimated ratios of predicted geometric means of CD8 counts and the geometric CD4:CD8 ratio. 95% confidence intervals displayed within brackets.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| BaselineCD4 countcells/mm3 | 0 to 3 years post-ART |  | 3 to 6 years post-ART |  | 6 to 9 years post-ART |
| CD4 count | CD8 count | Ratio CD4:CD8 |  | CD4 count | CD8 count | Ratio CD4:CD8 |  | CD4 count | CD8 count | Ratio CD4:CD8 |
| 0 to 24 | 11.5\*[11.1, 11.9] | 2.28[2.20, 2.35] | 5.04[4.85, 5.23] |  | 1.26[1.21, 1.30] | 0.96[0.93, 0.98] | 1.31[1.27, 1.36] |  | 1.27[1.23, 1.31] | 1.02[1.00, 1.04] |  1.25[1.21, 1.29] |
| 25 to 49 | 4.58[4.39, 4.78] | 1.66[1.59, 1.73] | 2.76[2.64, 2.89] |  | 1.24[1.19, 1.29] | 0.98$[0.95, 1.01] | 1.27[1.22, 1.32] |  | 1.19[1.14, 1.23] | 0.99[0.97, 1.02] |  1.20[1.15, 1.24] |
| 50 to 99 | 2.75[2.65, 2.84] | 1.31[1.27, 1.35] | 2.10[2.02, 2.18] |  | 1.22[1.18, 1.26] | 0.98[0.96, 1.01] | 1.24[1.20, 1.28] |  | 1.18[1.14, 1.21] | 0.97[0.95, 0.99] |  1.22#[1.18, 1.26] |
| 100 to 199 | 1.78[1.74, 1.82] | 1.06[1.04, 1.09] | 1.68[1.64, 1.72] |  | 1.09[1.07, 1.12] | 0.99[0.97, 1.00] | 1.11[1.08, 1.13] |  | 1.13[1.11, 1.15] | 0.98[0.96, 0.99] |  1.16[1.14, 1.18] |
| 200 to 349 | 1.41[1.38, 1.43] | 0.96[0.94, 0.98] | 1.46[1.44, 1.49] |  | 1.01[0.99, 1.03] | 0.98[0.97, 0.99] | 1.03[1.01, 1.05] |  | 1.10[1.09, 1.12] | 0.96[0.95, 0.97] |  1.15[1.13, 1.17] |
| 350 to 499 | 1.18[1.15, 1.21] | 0.95[0.93, 0.97] | 1.24[1.21, 1.28] |  | 0.93[0.91, 0.95] | 0.97[0.95, 0.99] | 0.96[0.94, 0.98] |  | 1.11[1.09, 1.13] | 0.96[0.95, 0.97] |  1.15[1.13, 1.18] |
|  500 | 0.96[0.94, 0.99] | 0.94[0.91, 0.96] | 1.03[1.00, 1.06] |  | 0.84[0.82, 0.86] | 0.96[0.94, 0.98] | 0.88[0.86, 0.90] |  | 1.08[1.06, 1.11] | 0.95[0.94, 0.96] |  1.14[1.12, 1.16] |

\* Interpretation of geometric ratio: Among patients who experienced virological failure with baseline CD4 count 0 to 24 cells/mm3, geometric mean CD4 count at 3 years was close to 12 times higher than the geometric mean CD4 count at start of ART.

$ Interpretation of geometric ratio: Among patients who experienced virological failure with baseline CD4 count 25 to 49 cells/mm3, geometric mean CD8 count at 6 years post-ART was 2% lower compared to the geometric mean CD8 count at 3 years post-ART.

# Interpretation of geometric ratio: Among patients who experienced virological failure with baseline CD4 count 50 to 99 cells/mm3, geometric CD4:CD8 ratio at 9 years post-ART was 22% higher than the geometric CD4:CD8 ratio at 6 years post-ART.